XOMA Royalty Corporation (NASDAQ:XOMA) Given Consensus Rating of “Hold” by Analysts

Shares of XOMA Royalty Corporation (NASDAQ:XOMA) have been assigned an average rating of “Hold” from the five brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $65.00.

Several research firms have recently weighed in on XOMA. HC Wainwright reiterated a “buy” rating on shares of XOMA Royalty in a research note on Thursday. UBS Group set a $76.00 price objective on XOMA Royalty in a research note on Tuesday. Weiss Ratings restated a “hold (c-)” rating on shares of XOMA Royalty in a research note on Monday. Zacks Research cut shares of XOMA Royalty from a “hold” rating to a “strong sell” rating in a research report on Tuesday, November 18th. Finally, Wall Street Zen downgraded shares of XOMA Royalty from a “buy” rating to a “hold” rating in a report on Saturday, November 15th.

XOMA Royalty Price Performance

Shares of XOMA stock traded down $8.35 during mid-day trading on Thursday, reaching $26.01. The company’s stock had a trading volume of 191,505 shares, compared to its average volume of 48,129. The firm’s 50-day moving average is $33.86 and its two-hundred day moving average is $31.01. The company has a market cap of $322.08 million, a P/E ratio of 35.27 and a beta of 0.94. XOMA Royalty has a 1-year low of $18.35 and a 1-year high of $39.92. The company has a debt-to-equity ratio of 1.07, a quick ratio of 3.91 and a current ratio of 3.91.

XOMA Royalty (NASDAQ:XOMA) last issued its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.33). XOMA Royalty had a net margin of 32.28% and a return on equity of 2.91%. The business had revenue of $9.35 million for the quarter, compared to analyst estimates of $11.47 million. On average, research analysts predict that XOMA Royalty will post -1.41 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Thomas M. Burns sold 4,330 shares of the stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $35.99, for a total transaction of $155,836.70. Following the sale, the chief financial officer owned 30,079 shares in the company, valued at approximately $1,082,543.21. This represents a 12.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Owen Hughes purchased 100,000 shares of the business’s stock in a transaction that occurred on Thursday, December 4th. The stock was acquired at an average cost of $25.05 per share, with a total value of $2,505,000.00. Following the completion of the acquisition, the chief executive officer directly owned 102,000 shares of the company’s stock, valued at $2,555,100. The trade was a 5,000.00% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders own 9.10% of the company’s stock.

Institutional Investors Weigh In On XOMA Royalty

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Woodline Partners LP grew its position in shares of XOMA Royalty by 16.5% during the 3rd quarter. Woodline Partners LP now owns 209,945 shares of the biotechnology company’s stock worth $8,091,000 after buying an additional 29,715 shares during the period. Vanguard Group Inc. lifted its stake in XOMA Royalty by 4.6% in the third quarter. Vanguard Group Inc. now owns 668,111 shares of the biotechnology company’s stock valued at $25,749,000 after buying an additional 29,298 shares in the last quarter. Stonepine Capital Management LLC raised its holdings in shares of XOMA Royalty by 17.2% during the second quarter. Stonepine Capital Management LLC now owns 152,143 shares of the biotechnology company’s stock worth $3,834,000 after acquiring an additional 22,330 shares during the period. Occudo Quantitative Strategies LP acquired a new position in XOMA Royalty in the 2nd quarter worth $527,000. Finally, Panagora Asset Management Inc. acquired a new position in shares of XOMA Royalty during the second quarter worth about $463,000. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.